GE HealthCare Technologies Inc. (GEHC) 2023 Q1 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good day, ladies and gentlemen, and welcome to the GE Healthcare First Quarter 2023 Earnings Conference Call. My name is Olivia, and I'll be your conference coordinator today. As a reminder, this conference is being recorded.

    各位女士、先生,大家好,歡迎參加 GE HealthCare 2023 年第一季財報電話會議。我是 Olivia,今天將擔任會議協調人。提醒各位,本次會議將進行錄音。

  • I would now like to turn the program over to your host for today's conference, Carolynne Borders, Chief Investor Relations Officer. Please proceed.

    現在我想把會議交給今天的主持人——投資人關係長(Chief Investor Relations Officer)Carolynne Borders。請開始。

  • Carolynne Borders - Chief IR Officer

    Carolynne Borders - Chief IR Officer

  • Thanks, Olivia. Welcome to GE HealthCare's First Quarter 2023 Earnings Call. I'm joined by our President and CEO, Peter Arduini; and Vice President and CFO, Helmut Zodl.

    謝謝你,Olivia。歡迎各位參加 GE HealthCare 2023 年第一季財報電話會議。我與我們的總裁暨執行長 Peter Arduini,以及副總裁暨財務長 Helmut Zodl 一同出席。

  • Our conference call remarks will include both GAAP and non-GAAP financial results. Reconciliations between GAAP and non-GAAP measures can be found in today's press release and in the presentation slides available on our website. During this call, we'll make forward-looking statements about our performance. These statements are based on how we see things today. As described in our SEC filings, actual results may differ materially due to risks and uncertainties.

    我們在電話會議中的發言將同時包含 GAAP 與非 GAAP 財務結果。GAAP 與非 GAAP 指標之間的調節表可見於今日新聞稿,以及我們網站上提供的簡報投影片。在本次會議中,我們將就公司表現發表前瞻性陳述。這些陳述係基於我們目前對情勢的看法。如同我們向 SEC 提交的文件所述,實際結果可能因風險與不確定性而出現重大差異。

  • And with that, I'll hand the call over to Peter.

    那麼,我把電話交給 Peter。

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • Thank you, Carolynne, and good morning, everyone. I'm very pleased by the solid performance we delivered in our first quarter as an independent company.

    謝謝你,Carolynne,各位早安。作為獨立公司,我們在第一季交出穩健的表現,令我非常欣慰。

  • The momentum we demonstrated last year has continued, and I'd like to thank our teams across the world for their continued dedication to executing on our precision care strategy.

    我們去年展現的動能持續延續,我要感謝全球各地團隊持續投入,致力於落實我們的精準照護策略。

  • We delivered strong 12% year-over-year organic revenue growth with contributions coming from all of our segments, driven by increased fulfillment, improved pricing and commercial execution. We expanded adjusted EBIT margin year-over-year through price and lean initiatives focused on cost and operational effectiveness and we're on track to achieve our margin expansion goals for the year.

    我們實現強勁的有機營收年增 12%,所有事業部門皆有貢獻,主要受惠於履約交付增加、定價改善以及商務執行力提升。我們透過價格與精實(lean)措施(聚焦成本與營運效能)使調整後 EBIT 利潤率較去年擴張,並且正按計畫達成今年的利潤率擴張目標。

  • We continue to monitor customer prioritization of capital purchases of our products, and we are cautiously optimistic given resilient end market demand. Supply chain challenges are improving, giving us line of sight throughout the remainder of the year.

    我們持續觀察客戶對我們產品資本性採購的優先順序;鑑於終端市場需求具韌性,我們保持審慎樂觀。供應鏈挑戰正在改善,使我們對今年剩餘期間的能見度提升。

  • We continue to invest organically to deliver long-term growth, demonstrated by the 13% year-over-year increase in R&D in the first quarter, in line with top line growth.

    我們持續進行有機投資以推動長期成長;第一季研發(R&D)年增 13%,與營收成長步調一致,便是明證。

  • In addition, we acquired Caption Health and IMACTIS, which provide us access to new technologies, markets and clinical capabilities. I also want to highlight today's declaration by our Board of a $0.03 dividend for the first quarter of 2023. This reflects our confidence in the durability of our cash generation, a disciplined capital allocation strategy and our commitment to returning value to shareholders.

    此外,我們收購了 Caption Health 與 IMACTIS,讓我們得以接觸新技術、新市場與新的臨床能力。我也要強調,董事會今日宣布 2023 年第一季每股股利 0.03 美元。這反映我們對現金創造能力持久性的信心、嚴謹的資本配置策略,以及回饋股東價值的承諾。

  • Overall, the momentum we see in our business gives us confidence in our ability to deliver on our full year 2023 guidance.

    整體而言,我們在業務上看到的動能,讓我們對達成 2023 年全年財測指引更具信心。

  • With that, let me hand the call over to Helmut to walk through our financials and business segment performance.

    接下來,我把電話交給 Helmut,請他說明我們的財務表現與各事業部門的營運表現。

  • Helmut Zodl - CFO

    Helmut Zodl - CFO

  • Thanks, Pete. Turning to our financial performance. For the first quarter of 2023, revenues of $4.7 billion increased 8% year-over-year and grew double digits at 12% organically. This was primarily driven by strong product growth across all segments.

    謝謝你,Pete。接著看我們的財務表現。2023 年第一季,營收 47 億美元,年增 8%,有機成長達雙位數的 12%。這主要由所有事業部門的強勁產品成長所帶動。

  • Adjusted EBIT margin improved year-over-year to 14.1%, growing 150 basis points on a stand-alone basis versus last year. Margin was up to the higher volume, which was partially offset by the mix of products versus services. In addition, we were able to mostly offset inflation and play investments through our pricing and productivity actions. But we are pleased with our margin performance during the quarter. There is room for more improvement. We have lean action plans in place to continue to expand margins further through volume, price and productivity initiatives across the company.

    調整後 EBIT 利潤率年增至 14.1%,以獨立公司口徑較去年提升 150 個基點。利潤率受惠於較高的出貨量,但部分被產品與服務組合變化所抵銷。此外,我們透過定價與生產力提升措施,大致抵銷通膨與投資的影響。我們對本季利潤率表現感到滿意,但仍有進一步改善空間。我們已制定精實行動計畫,將持續透過全公司範圍的量、價與生產力措施,進一步擴大利潤率。

  • Adjusted EPS was $0.85, up 35% on a stand-alone basis, driven by our strong revenue growth as well as margin expansion efforts. Free cash flow of $325 million was down $46 million, as expected based on the spin-related items, which I will discuss shortly.

    調整後每股盈餘(Adjusted EPS)為 0.85 美元,以獨立公司口徑年增 35%,主要受惠於強勁營收成長以及利潤率擴張努力。自由現金流為 3.25 億美元,較去年減少 4,600 萬美元,符合預期,主要因分拆(spin)相關項目所致,我稍後會說明。

  • Total company book-to-bill, which, as a reminder, is a calculation of total orders divided by total revenue was 1.01x. This was driven by strong revenue growth across all our segments, led by recurring PDx sales.

    全公司訂單出貨比(book-to-bill;提醒各位,其計算方式為總訂單除以總營收)為 1.01 倍。這反映我們各事業部門的強勁營收成長,其中以經常性 PDx 銷售為主要帶動。

  • We continue to see customers invest in solutions that drive better clinical insights and productivity across the U.S., China and Europe.

    我們持續看到客戶在美國、中國與歐洲投資於可帶來更佳臨床洞察與生產力的解決方案。

  • Moving to revenue performance. We grew 12% organically year-over-year. Foreign exchange was a headwind of 4% to revenue growth during the quarter. On a reported basis, product revenue increased 12% year-over-year driven by PDx sales with strong demand from increased procedures. Services revenue grew 1% versus the first quarter of 2022. Our strong product growth will translate to services growth as we go forward.

    接著看營收表現。我們有機營收年增 12%。本季匯率對營收成長造成 4% 的不利影響。以報表口徑來看,產品營收年增 12%,主要由 PDx 銷售帶動,且因手術/檢查量增加而需求強勁。服務營收較 2022 年第一季成長 1%。隨著產品成長延續,未來也將帶動服務成長。

  • From a regional perspective, we are pleased to see all regions growing with China up double digits. We are pleased with our margin performance this quarter. As we continue to focus on improvements in delivery, price and productivity. We delivered a positive sales price for 4 consecutive quarters with growth in all segments. These efforts combined with our productivity initiatives enabled us to generate year-over-year and sequential gross margin expansion. We also continue to see supply constraint easing with spot price and logistics costs down sequentially and year-over-year.

    從區域來看,我們很高興看到所有地區皆成長,其中中國呈現雙位數成長。我們對本季利潤率表現感到滿意,並將持續聚焦交付、價格與生產力的改善。我們已連續 4 個季度實現正向售價(sales price),且所有事業部門皆有成長。這些努力結合生產力措施,使我們的毛利率較去年同期及較前一季皆有所擴張。我們也持續看到供應限制緩解,現貨價格與物流成本較前一季及較去年同期均下降。

  • The actions we've taken to broaden our supply base coupled with the continuous application of lean principles has helped us to requalify almost 8,000 parts since COVID began. This has led to the lowest number of red flag parts since the first quarter of 2021, enabling us to deliver for patients and customers, which is our top priority.

    我們為擴大供應來源所採取的行動,加上持續導入精實原則,自 COVID 開始以來已協助我們重新認證近 8,000 個零件。這使得紅旗零件(red flag parts)數量降至自 2021 年第一季以來最低,讓我們能為病患與客戶如期交付——這是我們的首要任務。

  • As we look at our platforming initiatives, we have made good progress in CT with increased standardization of components across the portfolio. We've identified opportunities for simplification in sourcing, purchasing and manufacturing. We are in the process of implementing similar changes in MR.

    就平台化(platforming)計畫而言,我們在 CT 方面已取得良好進展,提升了產品組合中零組件的標準化程度。我們也找到了在採購來源、採購作業與製造方面的簡化機會。目前我們正著手在 MR 推動類似變革。

  • Following our spin-off from GE, we are on track with planned exit of TSAs, with approximately 40 exited to date. We remain focused on reducing G&A costs for example, with real estate expense and IT costs.

    自從自 GE 分拆後,我們正按計畫退出過渡服務協議(TSA),截至目前約已退出 40 項。我們仍專注於降低一般與管理(G&A)成本,例如不動產費用與 IT 成本。

  • Moving forward, we see opportunities to expand margins through additional actions for instance, in logistics with greater shift from air to ocean and greater platform standardization.

    展望未來,我們看到透過更多措施擴大利潤率的機會,例如在物流方面進一步由空運轉向海運,以及更高程度的平台標準化。

  • Before I get into the segment commentary, let me remind you that in 2023, approximately $200 million of recurring stand-alone costs will be impacting our segment EBIT margin rates. These costs are generally allocated based on the revenue and did not exist in 2022.

    在我進入各事業部門說明之前,先提醒各位:2023 年約有 2 億美元的經常性獨立公司成本將影響我們各事業部門的 EBIT 利潤率。這些成本通常依營收分攤,且在 2022 年並不存在。

  • Turning to imaging. We saw strong organic revenue growth, up 12% year-over-year. This was led by MR as well as molecular imaging and CT, driven by supply chain fulfillment improvement and growth in revenue from MPIs. We expect continued high growth throughout the first half of 2023 that will normalize throughout the rest of the year.

    接著看影像(Imaging)業務。我們看到強勁的有機營收成長,年增 12%。成長主要由 MR,以及分子影像與 CT 帶動,受惠於供應鏈履約改善,以及來自 MPIs 的營收成長。我們預期 2023 年上半年將維持較高成長,並在今年其餘期間趨於常態。

  • Imaging demand is expected to remain healthy, supporting top line growth. Segment EBIT margin of 7.7% declined 120 basis points year-over-year as planned investments and mix outweighed higher volume. Productivity and pricing initiatives more than offset inflation. We expect sequential margin rate improvement as we move throughout the year.

    影像需求預期將維持健康,支撐營收成長。事業部門 EBIT 利潤率為 7.7%,年減 120 個基點,符合規劃,主要因計畫性投資與產品組合影響大於出貨量提升。生產力與定價措施已足以抵銷通膨影響。我們預期隨著年度推進,利潤率將逐季改善。

  • Through lean efforts in imaging, we initiated a rolling 13-week schedule to maximize factory output and customer satisfaction. This will improve fulfillment as well as working capital.

    透過影像業務的精實努力,我們啟動了滾動式 13 週排程,以最大化工廠產出與客戶滿意度。這將改善履約交付並優化營運資金。

  • Overall, we expect steady growth in demand in 2023 with a number of drivers, including a continuous backlog of procedures, expanding indications for high-end diagnostic exams and new therapies requiring precision imaging.

    整體而言,我們預期 2023 年需求將穩健成長,驅動因素包括:持續累積的檢查待處理量(backlog)、高階診斷檢查適應症擴大,以及需要精準影像的新療法。

  • Moving to ultrasound. We saw strong organic revenue growth, up 10% year-over-year, led by cardiovascular, general imaging and women's health products. This was driven by MPIs and improving supply chain fulfillment with few electronic component shortages.

    接著看超音波(Ultrasound)業務。我們看到強勁的有機營收成長,年增 10%,主要由心血管、一般影像與婦女健康產品帶動。成長受惠於 MPIs,以及供應鏈履約改善,電子元件短缺情況不多。

  • While we expect growth to normalize as we move throughout the rest of the year, we continue to see strong customer demand in both hospital and other care settings. Segment EBIT margin of 24.1%, was up 50 basis points year-over-year. We realized benefits from productivity and price initiatives, along with volume growth. This enabled us to offset headwinds from inflation and planned investments, including the Caption Health acquisition.

    雖然我們預期隨著今年其餘期間推進,成長將趨於常態,但我們仍看到醫院及其他照護場域的客戶需求強勁。事業部門 EBIT 利潤率為 24.1%,年增 50 個基點。我們在生產力與定價措施以及出貨量成長方面取得效益,使我們得以抵銷通膨與計畫性投資(包括收購 Caption Health)帶來的不利影響。

  • We expect the EBIT margin rate will remain generally in line with the prior year. We continue to focus on patients and customer-centric innovation, especially digital and artificial intelligence solutions.

    我們預期 EBIT 利潤率將大致與前一年持平。我們持續聚焦於病患與以客戶為中心的創新,特別是數位與人工智慧解決方案。

  • Moving to Patient Care Solutions. Revenue was up 11% organically, driven by volume and price. This resulted from greater backlog fulfillment as supply challenges eased, particularly for electronic components. We benefited from dual site production for highly constrained products.

    接著談病患照護解決方案(Patient Care Solutions)。營收有機成長 11%,主要由銷量與價格帶動。這源於供應挑戰緩解後,積壓訂單的履約增加,尤其是電子元件。我們也受惠於對高度受限產品採取雙廠區生產。

  • Revenue was also driven by the launch of key MPIs contributing to increased volume, such as CARESCAPE Canvas and the B100 series of acute care monitors. PCS backlog remained strong, which will contribute to revenue growth into the future. We expect quarterly revenue dollars to remain relatively consistent throughout 2023. PCS margins of 14% increased 490 basis points compared to the first quarter of last year, driven by productivity, price and volumes. These are partially offset by inflation as well as planned investments.

    營收亦受關鍵 MPI 的推出所帶動,進而提升銷量,例如 CARESCAPE Canvas 以及 B100 系列急性照護監護儀。PCS 的積壓訂單仍然強勁,將在未來持續貢獻營收成長。我們預期 2023 年各季營收金額將維持相對一致。PCS 利潤率為 14%,較去年第一季提升 490 個基點,主要由生產力、價格與銷量帶動;但部分被通膨以及計畫性投資所抵銷。

  • Productivity in the first quarter was driven by favorable logistics and lower spot price. We expect EBIT margin rate to normalize throughout 2023.

    第一季的生產力提升主要來自有利的物流條件與較低的即期價格。我們預期 EBIT 利潤率將在 2023 年逐步回歸常態。

  • Moving to Pharmaceutical Diagnostics. We saw strong organic revenue growth, up 19% year-over-year, driven by price, increased procedures and the stabilization of supply. We expect continued revenue growth for the year based on favorable comparisons in the second quarter and the fourth quarter.

    接著談製藥診斷(Pharmaceutical Diagnostics)。我們看到強勁的有機營收成長,年增 19%,主要由價格、處置量增加以及供應穩定所帶動。我們預期在第二季與第四季的有利比較基期下,全年營收將持續成長。

  • Segment EBIT margin of 27.8% declined 70 basis points year-over-year, mainly driven by raw material inflation and planned investments. This was partially offset by price and volume and productivity which also drove full 80 basis points of sequential improvement. We continue to expect this segment to deliver strong EBIT margin performance. As we look ahead, we are investing in capacity to meet future customer demand.

    部門 EBIT 利潤率為 27.8%,年減 70 個基點,主要由原物料通膨與計畫性投資所致;部分被價格與銷量,以及生產力所抵銷,後者亦帶來連續季改善 80 個基點。我們仍預期該部門將展現強勁的 EBIT 利潤率表現。展望未來,我們正投資產能以滿足未來客戶需求。

  • Next, I'll walk through our cash performance. During the quarter, we generated $325 million of free cash flow. This was down $46 million year-over-year, impacted by $85 million of incremental post-retirement benefit payments and $42 million of interest payments, which were not in our 2022 actuals. Without these new cost-related items, year-over-year free cash flow would have been positive for the quarter.

    接下來我將說明我們的現金表現。本季我們產生 3.25 億美元的自由現金流,較去年同期減少 4,600 萬美元,主要受 8,500 萬美元的新增退休後福利給付,以及 4,200 萬美元的利息支付影響;這些在 2022 年實際數中並不存在。若不計入這些新的成本相關項目,本季自由現金流將較去年同期為正成長。

  • Working capital improved year-over-year primarily driven by collections and inventory efficiency. We have leveraged lean to implement a daily inventory management system. In the first quarter, we achieved solid results from controlling and better predicting inventory inputs and outputs with shorter lead times and improved revenue conversion cycle. As a result, we saw faster inventory turns and over 100 million of improvement in intra-quarter inventory.

    營運資金較去年同期改善,主要由收款與存貨效率帶動。我們運用精實(lean)導入每日存貨管理系統。第一季,我們透過更短的交期與改善的營收轉換週期,在控管並更好地預測存貨流入與流出方面取得穩健成果。因此,我們看到存貨周轉加快,且季內存貨改善超過 1 億美元。

  • Strong cash flow generation will allow us to pay down debt and invest organically and inorganically in our business. We are pleased to initiate a dividend with opportunity for growth over time. Our dividend philosophy is driven by prudent capital planning as well as a strong revenue and earnings growth potential and a robust free cash flow profile. Our balance sheet remains strong with significant financial flexibility.

    強勁的現金流產生能力將使我們得以償還債務,並以有機與無機方式投資於業務。我們很高興啟動股利,並有機會隨時間成長。我們的股利理念係基於審慎的資本規劃,以及強勁的營收與獲利成長潛力與穩健的自由現金流特性。我們的資產負債表仍然強健,具備顯著的財務彈性。

  • Let's move now to our outlook. For the full year of 2023, we are reaffirming our guidance. We continue to expect year-over-year organic revenue growth in the range of 5% to 7%, with strong organic growth in the first half of the year versus the second half. In line with seasonality, we expect revenue dollars to grow first half to second half. Our current view is a foreign exchange headwind of less than 1 percentage point for the year.

    接著談我們的展望。針對 2023 全年,我們重申既有指引。我們仍預期有機營收年增介於 5% 至 7%,且上半年有機成長將強於下半年。依季節性因素,我們預期營收金額將由上半年成長至下半年。我們目前的看法是,全年外匯逆風小於 1 個百分點。

  • We continue to expect full year adjusted EBIT margin to be in the range of 15% to 15.5%. This would represent an expansion of 50 to 100 basis points over the 2022 stand-alone adjusted EBIT margin of 14.5%. We also expect to see an increase in adjusted EBIT margin rate from the first half of the year to the second half, driven by higher volume and productivity benefits.

    我們仍預期全年調整後 EBIT 利潤率將介於 15% 至 15.5%。這相當於較 2022 年獨立(stand-alone)調整後 EBIT 利潤率 14.5% 擴張 50 至 100 個基點。我們也預期調整後 EBIT 利潤率將由上半年提升至下半年,主要由更高的銷量與生產力效益所帶動。

  • We expect R&D investment to grow at the higher end of the 2023 organic revenue growth range. Our guidance for adjusted effective tax rate remains in the range of 23% to 25%. Our full year 2023 adjusted EPS is unchanged in the range of $3.60 to $3.75, representing 7% to 11% growth. This compares to 2022 stand-alone adjusted EPS of $3.38. We continue to expect free cash flow conversion to be 85% or more for the full year.

    我們預期研發(R&D)投資成長將位於 2023 年有機營收成長區間的高端。我們對調整後有效稅率的指引仍為 23% 至 25%。我們 2023 全年調整後 EPS 維持不變,介於 3.60 至 3.75 美元,代表 7% 至 11% 的成長;相較之下,2022 年獨立調整後 EPS 為 3.38 美元。我們仍預期全年自由現金流轉換率為 85% 或以上。

  • Our cash flow outlook assumes that the legislation requiring R&D capitalization for tax purposes is repealed or deferred beyond 2023. The free cash flow impact of this legislation would represent up to 10 points of free cash flow conversion for the year. For 2023, we expect capital expenditures to be in the range of $350 million to $400 million.

    我們的現金流展望假設:要求就稅務目的將研發支出資本化的相關立法將被廢止,或延後至 2023 年之後。該立法對自由現金流的影響,全年最多可能相當於自由現金流轉換率的 10 個百分點。針對 2023 年,我們預期資本支出介於 3.5 億至 4 億美元。

  • I'd like to add that our second and fourth quarter cash flow will be impacted by interest payments as roughly 75% of our interest expense related to our long-term debt is paid out in these quarters. Given this interest payment timing, we expect lower cash generation in the second quarter versus the first quarter.

    我想補充的是,我們第二季與第四季的現金流將受到利息支付影響,因為與長期債務相關的利息費用約有 75% 會在這兩個季度支付。鑑於此利息支付時點,我們預期第二季的現金產生將低於第一季。

  • Cash flow will be substantially higher in the second half of the year relative to the first half due to typical cash seasonality and annual timing of supplier and compensation payments.

    由於典型的現金季節性,以及供應商與薪酬支付的年度時點安排,下半年現金流將顯著高於上半年。

  • In closing, it has been a strong start to the year, and we are confident in reaffirming our guidance.

    總結而言,今年開局強勁,我們有信心重申我們的指引。

  • Now I'll hand back to Pete.

    現在我把時間交還給 Pete。

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • Thank you, Helmut. Before turning to Q&A, I want to provide an update on some exciting focus areas in our business. In Imaging, we're energized about the developmental advancements we're making with photon counting CT technology for improved spectral and spatial resolution, reduce radiation and enhanced contrast to noise ratio of tissue at a molecular level. This step change in technology will help provide clinicians with more capabilities to significantly increase imaging performance across a variety of care pathways.

    謝謝你,Helmut。在進入問答之前,我想就我們業務中一些令人振奮的重點領域提供最新進展。在影像(Imaging)方面,我們對於以光子計數 CT 技術所取得的研發進展感到振奮,該技術可提升光譜與空間解析度、降低輻射,並在分子層級提升組織的對比雜訊比。這項技術的躍升將協助臨床醫師獲得更多能力,於多種照護路徑中顯著提升影像表現。

  • We believe we're on the right path towards the industry's second generation of photon counting technology with a deep silicon approach for even better resolution and clinical results. This technology will expand our imaging capability into high pitch helical and gated cardiac imaging, which are just a few of our important milestones in development.

    我們相信,我們正走在正確的道路上,邁向產業第二代光子計數技術,並採用深矽(deep silicon)方案以取得更佳解析度與臨床結果。此技術將把我們的影像能力擴展至高速螺旋掃描(high pitch helical)與心臟門控影像(gated cardiac imaging),這些只是我們研發中的幾項重要里程碑。

  • During the quarter, we also announced our acquisition of Caption Health, which expands access to Artificial Intelligence powered ultrasound imaging guidance for novice users. We're utilizing AI to provide real-time expert guidance to the user, and this helps us obtain diagnostic images providing advancements for patient care outside the typical hospital-only setting. And while we'll be starting with cardiac care pathway, we expect to extend this to other specialties in the future through continued R&D investment.

    本季我們也宣布收購 Caption Health,這將擴大新手使用者取得由人工智慧驅動的超音波影像導引的可及性。我們運用 AI 為使用者提供即時的專家指引,協助取得診斷影像,推動在典型僅限醫院的場域之外提升病患照護。雖然我們將先從心臟照護路徑開始,但我們預期未來透過持續的研發投資,將延伸至其他專科。

  • In our Patient Care Solutions business, we announced the FDA 510(k) clearance of our CARESCAPE Canvas monitoring platform. This interoperable solution can flex based on individual patients' needs for precise care. And the platform also offers continuous upgrade capability, so hospitals can adopt new technologies at their own pace for efficient fleet management across the different care pathways they serve. This series of MPIs represent initial steps towards realizing mission-critical infrastructure transformation that leverages the Edison platform and enables artificial intelligence in patient monitoring.

    在我們的病患照護解決方案(Patient Care Solutions)業務中,我們宣布 CARESCAPE Canvas 監測平台已取得 FDA 510(k) 核准。此一可互通(interoperable)的解決方案可依個別病患需求彈性調整,以提供精準照護。該平台亦提供持續升級能力,使醫院能以自身步調採用新技術,並在其服務的不同照護路徑間進行高效率的設備隊列管理。這一系列 MPI 代表我們朝向實現關鍵任務基礎設施轉型的初步步驟,該轉型將運用 Edison 平台並在病患監測中啟用人工智慧。

  • In neurology, we've been watching the emergence of disease-modifying therapies for Alzheimer's and the positive impact on patients. With the success of these advancements, we anticipate the need for more imaging. GE Healthcare is one of the only companies that has a full suite of products and solutions to support the entire Alzheimer's patient journey. And this includes our Vizamyl diagnostic agent and PET scanners, which can be used to confirm diagnosis and the MRI systems to monitor throughout the therapy.

    在神經科領域,我們一直關注阿茲海默症疾病修飾療法的興起及其對病患的正面影響。隨著這些進展的成功,我們預期將需要更多影像檢查。GE Healthcare 是少數能提供完整產品與解決方案組合、以支援阿茲海默症病患全旅程的公司之一,其中包括我們的 Vizamyl 診斷藥劑與 PET 掃描儀,可用於確認診斷,以及用於在治療期間持續監測的 MRI 系統。

  • I'm also pleased with the initial progress that we've made since forming our science and technology operations led by Dr. Taha Kass-Hout, our Chief Technology Officer. Specifically, we're driving cloud adoption to deliver on our digital innovation strategy and also building out these capabilities into our device portfolio.

    自從我們成立由首席技術長 Dr. Taha Kass-Hout 領導的科學與技術營運團隊以來,我也對我們取得的初步進展感到滿意。具體而言,我們正推動雲端採用以落實我們的數位創新策略,並同時將這些能力建置到我們的裝置產品組合中。

  • Last week, we met with many customers and collaborators at the Healthcare Information and Management Systems Society, the HIMSS Meeting, where we featured our growing portfolio of digital and AI innovations to help increase operational efficiencies, improve diagnostic confidence and support early interventions.

    上週,我們在醫療資訊與管理系統學會(Healthcare Information and Management Systems Society,HIMSS)年會(HIMSS Meeting)與許多客戶及合作夥伴會面;我們在會中展示了日益擴大的數位與 AI 創新產品組合,協助提升營運效率、提高診斷信心並支持更早期的介入。

  • In closing, I want to reiterate that we're encouraged by the strong results we delivered in the first quarter. Our margin improvement initiatives are taking hold, and we see ongoing opportunities to drive productivity and growth. Our backlog remains solid, and we're confident that we are investing in the right areas to drive long-term innovation. And with reaffirmation of our guidance to the year, we're demonstrating our commitment to delivering for customers and shareholders.

    最後,我想再次強調,我們對第一季交出的強勁成果感到鼓舞。我們的利潤率改善措施正在發揮成效,我們也看到持續推動生產力與成長的機會。我們的在手訂單依然穩健,並且我們有信心正投資於正確的領域以推動長期創新。隨著我們重申全年指引,我們也展現了為客戶與股東創造價值的承諾。

  • Lastly, our team continues to be passionate about making a difference for patients. We recently held our first Patient Care Week. Our employees had the opportunity to experience the real impact of our products, solutions and services and how they're driving and delivering better outcomes for patients and also access to care. This is a great example of the cultural transformation taking place at GE Healthcare.

    此外,我們的團隊仍然熱衷於為病患帶來改變。我們最近舉辦了第一屆「病患照護週」(Patient Care Week)。員工有機會親身體驗我們的產品、解決方案與服務所帶來的真實影響,以及它們如何推動並實現更佳的病患結果與照護可近性。這是 GE Healthcare 正在進行的文化轉型的一個很好的例子。

  • With that, we'd like to open it up for questions.

    接下來,我們想開放提問。

  • Carolynne Borders - Chief IR Officer

    Carolynne Borders - Chief IR Officer

  • Olivia, we're ready to open for questions.

    Olivia,我們已準備好開放提問。

  • Operator

    Operator

  • (Operator Instructions) And our first question coming from the line of Ryan Zimmerman with BTIG.

    (接線員指示)我們的第一個問題來自 BTIG 的 Ryan Zimmerman。

  • Ryan Benjamin Zimmerman - MD & Medical Technology Analyst

    Ryan Benjamin Zimmerman - MD & Medical Technology Analyst

  • Sorry, I was on mute there. Congrats guys. And just want to start off. So the book-to-bill ratio came in at 1.01. I think orders were down, if I'm not mistaken, from last year by about 3% -- 2.7%. But just correct me if I'm wrong on that, Helmut, because it's just a summation number in the GE deck from last year? And then how do you think about kind of the seasonality of this dynamic, the book-to-build ratio as we progress through the year?

    抱歉,我剛剛在靜音。恭喜各位。先從這裡開始:訂單出貨比(book-to-bill)是 1.01。我記得訂單量相較去年下降了大約 3%——2.7%。但如果我說錯了請糾正我,Helmut,因為這只是我從 GE 去年簡報裡加總出來的數字?另外,隨著今年進行,你們如何看待這個動態的季節性,也就是訂單出貨比在全年推進過程中的變化?

  • Helmut Zodl - CFO

    Helmut Zodl - CFO

  • Yes. Ryan, I think, let me probably remind you the calculation of the book-to-bill is orders over revenue. So our first quarter book-to-bill at 1.01 is really reflecting our 12% revenue growth. So with improved fulfillment and especially our PDx sales. In PDx, we have a 1:1 ratio of book-to-bill.

    是的,Ryan,我想先提醒你訂單出貨比的計算方式:訂單除以營收。因此,我們第一季 1.01 的訂單出貨比,實際上反映了我們 12% 的營收成長,這得益於交付能力的改善,尤其是我們的 PDx 銷售。在 PDx 方面,我們的訂單出貨比是 1:1。

  • The backlog, maybe if I'll cover that a little bit, grew sequentially. So our RPO is now at around $14.5 billion, which is up 1%, and we saw positive orders growth. We don't disclose order growth in details, but we saw positive order growth in the quarter. And our total backlog is close to $19 billion in this. Again, this was a very strong quarter in delivering top line revenue growth. At the same time, our RPO is slightly up on a year-to-year basis.

    至於在手訂單,我也補充說明一下:我們的 RPO(剩餘履約義務)較前一季成長,目前約為 145 億美元,年增 1%,而且本季我們看到訂單呈現正成長。我們不會揭露訂單成長的細節,但本季確實看到正向的訂單成長。我們的總在手訂單接近 190 億美元。再次強調,這是一個在營收成長方面表現非常強勁的季度;同時,我們的 RPO 也較去年同期略有上升。

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • And Ryan, I would just add, I think we had a strong quarter in Q1 of last year. The numbers came in this year right on track. We'll expect that to continue to grow. And again, just to emphasize Helmut's point, when you have a high performance on something like a flowable product like PDx and stuff, it fundamentally is kind of a net neutral one-to-one transfer through. But the team delivered what we needed to deliver, and we're on track here to what we believe we need for orders to grow throughout the year.

    Ryan,我再補充一點:我認為去年第一季本來就是很強的一季。今年的數字基本上符合預期,我們預期會持續成長。再次強調 Helmut 的重點,當你在像 PDx 這類可流動(flowable)的產品上表現很強時,本質上會呈現接近 1:1 的中性轉換。但團隊交付了我們需要交付的成果,我們也在軌道上,符合我們認為全年訂單需要成長的目標。

  • Ryan Benjamin Zimmerman - MD & Medical Technology Analyst

    Ryan Benjamin Zimmerman - MD & Medical Technology Analyst

  • Got it. Very helpful. And I just want to ask about -- we've heard some comments about the diagnostic pipeline improving and then driving the procedural environment. We heard that from some of the med tech peers last week. And Pete, I'd love to get your perspective on the environment, particularly from a diagnostics perspective, I mean, you're seeing it probably through some of the imaging volume and just kind of how you think about the balance of the year from a diagnostic screening perspective?

    了解,非常有幫助。我還想問一下——我們聽到一些評論說診斷端的管線正在改善,進而帶動手術/介入環境。上週我們也從一些醫療科技同業聽到類似說法。Pete,我很想聽聽你對整體環境的看法,特別是從診斷角度來看;你們可能會從影像檢查量等面向看到趨勢。你如何看待今年剩餘時間在診斷篩檢方面的平衡?

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • Yes, Ryan, it's a really interesting question. And obviously, we have a certain lens into it. But I think if you step back when I'm out on the road talking to customers, and I've been with quite a few recently, you're just seeing that almost any type of therapy, whether it be in the musculoskeletal, whether it be in the cardiac, oncology, everything is heavily gated by some level of diagnostic to choose a better decision whether it be an implant, some type of interventional device to precisely fit that patient.

    是的,Ryan,這是個非常有意思的問題,當然我們也有特定的觀察視角。不過如果退一步看,當我在外出差與客戶交流——最近也見了不少客戶——你會看到幾乎任何類型的治療,不論是肌肉骨骼、心臟、腫瘤等領域,都在某種程度上高度依賴診斷,來做出更好的決策,例如是否植入、或使用某種介入式器材,以便更精準地符合該病患的需求。

  • And so particularly in the imaging world, we're still seeing significant demand and procedures for customers, meaning that their backlogs are still quite long. And again, we don't think this is necessarily a blip. We think that with the rise of many new therapies whether it be TAVR or whether it be pharmaceuticals that require more follow-up and measurement, just the need for what we do to make sure that you're getting the optimization and outcome, but also managing cost is there.

    因此,特別是在影像領域,我們仍看到客戶端有顯著的需求與檢查/處置量,也就是說他們的待處理量(backlog)仍然相當長。而且我們不認為這只是短暫現象。我們認為,隨著許多新療法的興起,不論是 TAVR,或是需要更多追蹤與量測的藥物治療,對我們所做之事的需求——確保最佳化與結果,同時也管理成本——都確實存在。

  • So we see it quite strong. And it's interesting, it's not just a U.S. phenomena. I mean, we're seeing this in most markets around the world.

    所以我們看到的態勢相當強勁。而且有趣的是,這不只是美國的現象;我們在全球多數市場都看到了這種情況。

  • Helmut, I don't know if you want to add anything to that.

    Helmut,你是否想補充一下?

  • Helmut Zodl - CFO

    Helmut Zodl - CFO

  • Yes, maybe I'll add a little bit. I think we're spending a lot of time with our customers, especially devices and digital solutions, we were just at HIMSS in the last week, a lot of discussions, how our devices can really help drive productivity to reduce that, I would say, challenge on the backlog and the shortages on personnel that some of our customers are having. That's really a key focus of our customer, which drives demand.

    是的,我補充一點。我們花了很多時間與客戶交流,尤其是在設備與數位解決方案方面;我們上週也剛參加 HIMSS,進行了很多討論,探討我們的設備如何真正協助提升生產力,以緩解我會說的那種待處理量壓力,以及部分客戶面臨的人力短缺挑戰。這確實是客戶的關鍵關注點,也因此帶動需求。

  • Operator

    Operator

  • And our next question coming from the line of Anthony Petrone with Mizuho Group.

    下一個問題來自 Mizuho Group 的 Anthony Petrone。

  • Anthony Charles Petrone - MD & Senior Medical Devices, Diagnostics and Therapeutics Equity Research Analyst

    Anthony Charles Petrone - MD & Senior Medical Devices, Diagnostics and Therapeutics Equity Research Analyst

  • Congrats on a strong first quarter here. Maybe, Pete, a couple for you here. I'll just pick off where Ryan left off here. Maybe rounding out just the discussions with hospital customers, what are you hearing on the capital spending front? We've heard some, in certain cases, still very bullish outlook, certainly for imaging, but on certain high-ticket items, there seems to be a little bit of friction. So maybe just your thoughts on the CapEx environment. And then I'll have a couple of follow-ups.

    恭喜第一季表現強勁。Pete,我這邊有幾個問題。我先接著 Ryan 的話題:在與醫院客戶的討論中,你們在資本支出方面聽到什麼?我們聽到有些情況下仍然非常看多,尤其是影像領域;但在某些高單價項目上,似乎有一些摩擦。想請你談談 CapEx 環境的看法。之後我還有幾個追問。

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • Yes, Anthony. I would say not a lot has changed since we reported even in our fourth quarter from that standpoint. I think we're encouraged by kind of the steady recovery of the global procedures, which is really the underpinning of this, which says, if you have a lot of patients that need procedures, they need planning, they need evaluation done and you don't have enough equipment that drives demand.

    是的,Anthony。我會說從這個角度看,自從我們在第四季財報時報告以來,並沒有太多改變。我們受到鼓舞的是全球手術/處置量的穩定復甦,這是整體的根基:如果有很多病患需要處置,他們就需要規劃、需要評估,而當設備不足時,就會推動需求。

  • And again, it's not always new sockets. It may be software and upgrades to your fleet to bring new capabilities. So we see that happening. And if I just go around the world, China has strong growth. Obviously, COVID for a couple of years, things opened up, a lot of demand there.

    而且,這不一定總是新增設備(new sockets)。也可能是軟體與既有設備群(fleet)的升級,以帶來新的能力。我們確實看到這正在發生。如果我放眼全球,中國成長強勁。顯然在 COVID 的幾年之後,市場重新開放,累積了大量需求。

  • Our intercontinental markets, Southeast Asia and LatAm were seeing actually similar strong growth as specific countries and areas, Indonesia, different areas in Southeast Asia and Latin America, investing. Western Europe is quite stable. I think the continuation of some of the sick funds investments that took place coming out of COVID really just starting to deliver on that equipment.

    我們的跨洲市場(intercontinental markets),也就是東南亞與拉丁美洲(LatAm),也看到類似的強勁成長;一些特定國家與地區——印尼、東南亞不同地區以及拉丁美洲——都在投資。西歐相當穩定。我認為,COVID 之後一些疾病基金(sick funds)的投資延續下來,現在真的開始落地交付這些設備。

  • And the U.S. is, look, since COVID, people have been prioritizing capital. I mean, so that's no new news for us. But again, what we keep an eye on is what they're deciding to put it against. And I think with nursing costs starting to flatten out, you're seeing a little bit more of, I would say, positivity on that spend. That being said, we think we're going to be in a capital prioritization kind of focus throughout this year, which is why we're cautiously optimistic.

    至於美國,坦白說,自 COVID 以來,各機構一直在優先排序資本支出;這對我們來說不是新消息。但我們持續關注的是,他們決定把資本投向哪些項目。我認為隨著護理人力成本開始趨於平緩,你會看到在支出上出現更多、我會說的正向情緒。即便如此,我們認為今年仍會處於「資本優先排序」的環境之中,因此我們保持審慎樂觀。

  • Anthony Charles Petrone - MD & Senior Medical Devices, Diagnostics and Therapeutics Equity Research Analyst

    Anthony Charles Petrone - MD & Senior Medical Devices, Diagnostics and Therapeutics Equity Research Analyst

  • That's helpful. And then follow-up, one for you, Pete, and a quick one for Helmut on margin. Intrigued by the comments on Alzheimer's disease and maybe just a little bit of a description is, is that something that is driving demand now? And when you look out, how long do you think that tailwind to the business can be with just new drug therapies coming to market?

    這很有幫助。接著追問兩個問題:一個給你,Pete,另一個快速給 Helmut、關於毛利率。我對你們提到阿茲海默症的評論很感興趣,想請你稍微描述一下:這是否正在推動目前的需求?以及往前看,隨著新的藥物療法上市,你認為這股對業務的順風可以持續多久?

  • And then quickly for Helmut on margin, when we think about the $200 million of stand-alone costs, just sort of the outlook on when you can perhaps see leverage on those new costs that were brought into the business.

    然後快速問 Helmut 一個關於毛利率的問題:當我們思考那 2 億美元的獨立營運成本(stand-alone costs)時,想請你談談展望——你們大概何時能在這些新導入到業務中的成本上看到槓桿效益?

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • Yes, Anthony. Look, on the Alzheimer's point, no, I don't think we're really seeing any impact on demand to date. But when you look at what can come, what the pipeline looks like we think there's going to be larger demand. I'll even pull the lens back a little bit further. It ties into part of Ryan's question as well. I think, look, bigger picture, imaging capabilities and diagnostics used to kind of manage how devices are executed, but probably even more importantly, expensive pharmaceutical injectable therapeutics, how they're utilized, how they're titrated, how they may be dosed and the follow-ups on potential complications really seems to be a potential kind of norm in the future.

    是的,Anthony。關於阿茲海默症這點,坦白說,我不認為我們迄今真的看到對需求有任何影響。但當你看未來可能發生的事、以及研發管線的樣貌時,我們認為需求會變得更大。我甚至把視角再拉遠一點,這也和 Ryan 的問題部分相關。我想更大的趨勢是:影像能力與診斷過去多半用來管理器械如何執行,但也許更重要的是,對於昂貴的藥物注射型治療,如何使用、如何滴定(titrate)、如何給藥,以及對潛在併發症的追蹤,未來看起來很可能會成為一種常態。

  • So if you think about this case, neurosciences, if you think about in oncology with theranostics, if you think in cardiology with different follow-ups for structured heart or heart failure, we see that happening. And so we'll see how that plays out. But like in our case, where we make the actual tracer, Vizamyl for amyloid-beta plaque detection and quantification, really the only one that has that type of product that actually even colors that and separates it out. It hasn't been reimbursed.

    所以如果你想想這個案例——神經科學;如果你想想腫瘤科的診療一體化(theranostics);如果你想想心臟科針對結構性心臟病或心衰竭的不同追蹤,我們都看到這正在發生。因此我們會看看它如何發展。但就我們的情況而言,我們製造實際的示蹤劑(tracer)——Vizamyl,用於類澱粉 β 斑塊(amyloid-beta plaque)的偵測與定量;真正具備那種產品、能把它「上色」並加以區分的,基本上只有我們。但它尚未獲得給付(reimbursed)。

  • And so we believe once the therapies get reimbursement like in other therapy areas, the companion diagnostics also do, that's what will enable some of the growth. And so I'm optimistic, like most things, it will take a little bit of time. But over the next few years, I think there's going to be some interesting growth opportunities associated with that match up.

    因此我們相信,一旦這些療法像其他治療領域一樣獲得給付,伴隨式診斷(companion diagnostics)也會獲得給付,這將帶動部分成長。所以我很樂觀;和多數事情一樣,這需要一點時間。但在接下來幾年,我認為會有一些與這種搭配相呼應的有趣成長機會。

  • Helmut, do you want to take the margin question?

    Helmut,你要回答毛利率的問題嗎?

  • Helmut Zodl - CFO

    Helmut Zodl - CFO

  • Yes. So Anthony, I think around this $200 million of stand-alone costs, in 2023, we expect an estimated $200 million of those recurring incremental expenses. Those are primarily for support functions, so it's IT, treasury, IR and so forth. And these costs, they are not in our segment margins. They were not in our segment margins in 2022. We're allocating them in 2023 based on the revenue very generally. So I want to be sure that, that is well understood.

    好的。Anthony,關於這 2 億美元的獨立營運成本,我想說的是:在 2023 年,我們預期這些經常性(recurring)的增量費用約為 2 億美元。這些主要是支援性職能的成本,例如 IT、財務(treasury)、投資人關係(IR)等等。而且這些成本不包含在我們的分部毛利率(segment margins)中;在 2022 年也不在我們的分部毛利率裡。我們會在 2023 年非常概略地依營收來分攤它們。我想確保大家充分理解這一點。

  • And to your question, when we will see leverage against those one, to me, this is really dependent on how quickly we are exiting our TSAs. You saw me speak, we exited 40 TSAs in the first in the quarter. Here, we have more TSAs to exit that will take us into 2024. So I expect we'll see leverage against this $200 million of incremental recurring spin costs as we go into 2025 and '26, as we have fully exited on the TSA side and can really build our own infrastructure.

    至於你問何時會看到對這些成本的槓桿效益,對我來說,這真的取決於我們退出過渡服務協議(TSA)的速度。你聽到我提到,我們在本季第一季退出了 40 項 TSA。接下來還有更多 TSA 要退出,這會延續到 2024 年。因此我預期,當我們進入 2025 年與 2026 年、在 TSA 端完全退出並能真正建立自己的基礎設施後,我們會看到對這 2 億美元經常性增量分拆成本(spin costs)的槓桿效益。

  • Operator

    Operator

  • And our next question coming from the line of Jason Bednar with Piper Sandler.

    下一個問題來自 Piper Sandler 的 Jason Bednar。

  • Jason M. Bednar - Director & Senior Research Analyst

    Jason M. Bednar - Director & Senior Research Analyst

  • Congrats on a very nice start to the year. Maybe I'll start with organic growth. Just as we peel apart the components of the 1Q organic growth, are you able to quantify how much of that 12% may have come from pure price? It looks like you're calling out pricing tailwinds in each of the 4 segments. I'm just curious if we should be thinking in the area of 1% to 2%, 2% to 3%, et cetera, when we think at the corporate level? And then is that a sustainable figure as we look to future quarters? Or would you point us to maybe upward or downward bias in the pricing?

    恭喜今年開局非常漂亮。我先從有機成長談起。當我們拆解第一季有機成長的組成時,你們能否量化一下這 12% 中有多少是純粹來自價格?看起來你們在四個分部都提到定價順風。我只是好奇,若以公司整體層級來看,我們應該用 1% 到 2%、2% 到 3% 等哪個區間來思考?另外,展望未來幾季,這個數字是否可持續?或者你們會指引我們在定價上可能有上行或下行的偏向?

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • Yes, Jason, it's Pete. I'll comment and see if Helmut wants to add anything to it. I think so it's a really great result. All 4 of our segments delivering quite nicely for us. And so from an overall growth standpoint, we clearly saw volume as the key driver here and our ability to kind of move on our backlog as well as some sell and install business as well that was taking place in our -- and particularly our ultrasound business and then the flow with that's taking place in PDx and the Injectable business.

    是的,Jason,我是 Pete。我先回應,看看 Helmut 是否要補充。我認為這確實是非常好的成果。我們四個分部的表現都相當出色。就整體成長而言,我們清楚看到「量」是主要驅動因素,包含我們推進既有訂單(backlog)的能力,以及我們也有一些銷售與安裝(sell and install)的業務在進行——特別是在我們的超音波業務;另外在 PDx 與注射劑(Injectable)業務也有相應的動能。

  • I'd say we're in the 2% to 3% range relative to price coming through, and the vast majority of the rest of it is in pure volume and uplift.

    我會說價格貢獻大約在 2% 到 3% 的區間,其餘絕大多數來自純粹的量與提升(uplift)。

  • Helmut Zodl - CFO

    Helmut Zodl - CFO

  • Yes. Maybe I'll add a little bit of comment on that as well, Jason. What Pete said, this is our fourth quarter in a row now that we are seeing positive sales price. And as Pete said, 2% to 3% accretion we expect in 2023. And in the outer years, that might flatten out a little bit to 1% to 2%. But what's really most important is the value we are providing our customers in -- with those products. And we are not only focused on price, but also really focused on the gross margin expansion because as we see new MPIs, we're looking very carefully what's the price accretion but also what happens in around margin accretion with those products. And lots of initiatives in place around BCP and platforming that will help and support that.

    是的,Jason,我也補充一點。正如 Pete 所說,這已經是我們連續第四個季度看到正向的售價(sales price)。而且如 Pete 所述,我們預期 2023 年會有 2% 到 3% 的增益(accretion)。在更外圍的年度,可能會稍微趨於平坦,落在 1% 到 2%。但最重要的是我們透過這些產品為客戶提供的價值。我們不只聚焦在價格,也非常聚焦在毛利率擴張,因為當我們看到新的 MPI 時,我們會非常仔細地看價格增益,同時也看這些產品帶來的毛利率增益。我們在 BCP 與平台化(platforming)方面也有許多計畫在推進,將有助於並支持這些成果。

  • Jason M. Bednar - Director & Senior Research Analyst

    Jason M. Bednar - Director & Senior Research Analyst

  • All right. Very helpful. And I wanted to ask a follow-up just actually on Portrait Mobile. I think it was introduced almost a year ago. It's still pending 510(k), but you were showing it at HIMSS here recently. Can you discuss where you're at with the FDA in securing the approval? And then what early feedback can you share on Portrait Mobile for the markets in which it's available?

    好的,非常有幫助。我想追問其實是關於 Portrait Mobile。我記得它大約一年前就推出了。它仍在等待 510(k) 核准,但你們最近在 HIMSS 也展示了它。你們能否談談目前與 FDA 的進度、在取得核准方面走到哪一步?另外,對於已經上市的市場,你們能分享哪些關於 Portrait Mobile 的早期回饋?

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • Yes, Jason. So we're in with the agency. We would expect here in the first half of this year to be able to move through unless there's other follow-up questions and stuff. We're actually on the market in -- outside the United States, primarily EU. And if you think of the focus on Portrait Mobile, it really takes us into new territory. We haven't really been award-based monitoring company. And so that's really our first entree into the area. We've already had some really good feedback from different customers on enabling continuous monitoring the award.

    是的,Jason。我們正在與主管機關(agency)溝通中。我們預期在今年上半年能夠推進完成,除非還有其他追問或補件需求。我們其實已在美國以外的市場上市,主要是在歐盟(EU)。如果你想想 Portrait Mobile 的定位,它確實把我們帶進新的領域。我們過去並不是一家以病房(ward)為主的監測公司,因此這算是我們首次切入這個領域。我們已經從不同客戶那裡收到一些非常好的回饋,認為它能在病房端實現連續監測。

  • I think one of the bets that we're making is coming out of COVID, there tended to be more continuous O2, CO2, respiratory monitoring. And with the shortage of staff and stuff being able to instead of episodically, but constantly manage a patient, there's a big opportunity to manage your labor better by directly sending a message directly to a caregiver to check on that patient as opposed to just spot checking. So it's often running. We'll talk more about it here in coming quarters, but we feel quite good about that as well.

    我認為我們押注的一點是:COVID 之後,對更連續的 O2、CO2 與呼吸監測的需求增加。再加上人力短缺,能夠不再是間歇式(episodically)而是持續地管理病人,就有很大的機會透過更有效地配置人力來改善照護:例如直接發訊息給照護人員,請他去查看該病人,而不是只做抽查(spot checking)。所以這個產品正在運作中。我們會在接下來幾季再多談一些,但我們對此也相當有信心。

  • And then that's complemented with this introduction that we just received prove on, which is the CARESCAPE Canvas. And the CARESCAPE is a platform that actually has more ubiquitous use that can be used in acute care but also step down. And what customers have told us is the challenge they have is you have to buy a different box from everybody for the different areas. And CARESCAPE is one of those first platforms that enables you based on the acuity of the patient to add on more parameters. But it's also designed for a future where you can actually gather the data on the patient and be able to apply artificial intelligence against it to actually predict when that patient is going to have issues.

    此外,這也與我們剛獲得核准推出的產品相互補強,也就是 CARESCAPE Canvas。CARESCAPE 是一個平台,使用情境更普遍,可用於急性照護,也可用於次急性(step down)。客戶告訴我們,他們面臨的挑戰是:不同區域得向不同供應商買不同的盒子(設備)。而 CARESCAPE 是首批平台之一,能讓你依病人的病情嚴重度(acuity)加掛更多參數。同時它也為未來而設計:你可以蒐集病人資料,並在其上應用人工智慧,去預測病人何時可能出現問題。

  • And so that's kind of our vision of why we're so excited about monitoring is this potential in the future to be able to track constant patient -- constantly the patient as well as predict when there might be an issue. So both of those are 2 new platforms for us the first in many, many years, and we would expect that to be 2 of the horses in the monitoring group here that we'll be growing our business on.

    因此,這大概就是我們對於為何對監測如此興奮的願景:未來有機會能夠持續追蹤病患——不斷地監測病患,同時也能預測何時可能出現問題。所以這兩者對我們而言都是兩個全新的平台,是多年來首次出現的全新平台;我們預期它們將成為我們監測業務組合中兩匹重要的「戰馬」,我們將以此來擴大我們的業務。

  • Operator

    Operator

  • And our next question coming from the line of Edward Ridley-Day with Redburn.

    下一個問題來自 Redburn 的 Edward Ridley-Day。

  • Edward Nicholas Ridley-Day - Research Analyst

    Edward Nicholas Ridley-Day - Research Analyst

  • Congratulations on the strong quarter. Firstly, on Imaging, great start to the year. If you could perhaps help us with the phasing on the margin. I appreciate a lot of investment, some of which you've spoken to today, given the opportunity. But if there's more color you can give us on the phasing of the Imaging margins for the year and where we should end up, that would be helpful?

    恭喜本季表現強勁。首先談影像業務(Imaging),今年開局很好。若您能協助我們理解毛利率/利潤率在年度內的節奏(phasing)會很有幫助。我理解你們有大量投資,其中一些你們今天也提到了,且是基於機會所做的投入。但如果你們能就今年影像業務利潤率的分布節奏,以及我們最終應該落在什麼水準提供更多說明,將非常有幫助。

  • And I also had a follow-up question on Patient Care. Obviously, a very positive start to the year. You've mentioned some of them, but where were the particular strength in the product lines driving that growth? And also, if you can, can you give us an idea of how much of the growth in the first quarter was sort of backlog pull through?

    我還有一個關於病患照護(Patient Care)的追問。顯然今年開局非常正面。你們提到了一些因素,但究竟是哪些產品線的特別強勁帶動了這個成長?另外,如果可以的話,你們能否提供第一季成長中有多少是由積壓訂單(backlog)出貨所帶動的?

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • So Helmut, you want to start maybe with a comment on Imaging and then we'll jump on...

    Helmut,你要不要先就影像業務做個評論,然後我們再接著回答……

  • Helmut Zodl - CFO

    Helmut Zodl - CFO

  • So I'll start with Imaging margins. So obviously, we are very focused on expanding the EBIT margins in the high teens in the medium term for Imaging. And if you look at in the first quarter, our margins were at 7.0% or 8% for imaging both were slightly lower than what we saw in the fourth quarter, but there was a clear reason because we were shipping a higher and a component of hardware versus services in the quarter. But as we expect the services pull-through, we expect those margins to improve. And what we also still were impacted in the quarter was, I would say, the cost for inflation. So what we have seen of inventory that was sitting on the balance sheet for Imaging specifically, both bringing down that margin.

    我先從影像業務的利潤率談起。很明顯地,我們非常專注於在中期將影像業務的 EBIT 利潤率擴大到 10% 高段(high teens)。如果你看第一季,我們影像業務的利潤率約在 7.0% 或 8%;兩者都比第四季略低,但原因很清楚,因為本季出貨中硬體相對於服務的比重更高。但隨著我們預期服務的帶動效應(services pull-through)出現,我們預期利潤率會改善。此外,本季我們仍受到通膨成本的影響。我們看到特別是影像業務資產負債表上既有的庫存,對利潤率造成壓力,拉低了該利潤率。

  • And the last comment I want to make in this is also that our Imaging margins as well as the other segments were impacted by the segment recurring spin costs. So those $200 million, I just talked a little bit earlier, were roughly 100 basis points, which is impacting basically each of the segments. But we have confidence that the Imaging margins, as we go throughout the year, will improve accordingly as inflation is getting less and less.

    我最後想補充的是,我們的影像業務利潤率以及其他事業部,也受到事業部分拆(spin)相關的經常性成本影響。我稍早提到的那 2 億美元,約相當於 100 個基點,基本上影響到各個事業部。不過我們有信心,隨著年度推進,影像業務利潤率將會相應改善,因為通膨影響會愈來愈小。

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • Yes. I mean in the other aspect, as you could imagine, many of the Imaging products are much more sophisticated components, a lot more chips and stuff. And so some of those are burdened with, I'd say, higher cost items that we bought last year to make sure we could deliver through for customers. And as that inventory moves through, which we think will, as we move into the second half of the year, we'll see some margin lift from better productivities just from our sourcing standpoint.

    是的。另一個面向,如你所想像,許多影像產品包含更精密的零組件、更多晶片等等。因此其中一些承擔了我會說較高的成本項目——這些是我們去年為了確保能夠交付給客戶而採購的。隨著這些庫存逐步消化,我們認為在進入下半年時,僅就採購端(sourcing)的角度,因為生產力提升,我們會看到利潤率有所抬升。

  • To your question on PCS, yes, we were quite happy with the performance overall. It was reasonably a wide scale kind of success in the quarter. I mean, our Monitoring business was double digits. Our MIC business, which is into the neonatal area, was quite well and also our Anesthesia business. And I would highlight Anesthesia because actually, at the end of -- in last year, we actually received PMA for title control, which is actually kind of a management of kind of parameters of oxygen and capturing of the agents in a much more effective way, and we are able to -- be able to capture more growth because of that upgradability, but also some more value. So it's a good start to the year for our PCS business.

    針對你關於 PCS 的問題,是的,我們對整體表現相當滿意。本季的成功可說是相當全面。我們的監測(Monitoring)業務是雙位數成長;我們的 MIC 業務(新生兒領域)表現也相當不錯,麻醉(Anesthesia)業務亦然。我特別要強調麻醉,因為其實在去年年底,我們取得了針對 title control 的 PMA(上市前核准),這基本上是一種對氧氣等參數的管理,並能更有效地捕捉麻醉氣體(agents)。因此,憑藉這種可升級性以及更高的價值,我們能夠帶動更多成長。所以對我們的 PCS 業務而言,今年是個好的開局。

  • Operator

    Operator

  • And our next question coming from the line of Larry Biegelsen with Wells Fargo.

    下一個問題來自 Wells Fargo 的 Larry Biegelsen。

  • Lawrence H. Biegelsen - Senior Medical Device Equity Research Analyst

    Lawrence H. Biegelsen - Senior Medical Device Equity Research Analyst

  • I don't think there's been a question on farm diagnostics yet. That was extremely strong. Pete, help us understand how much that benefited from the comps year-over-year from the contract shortage. But even when I look at that business on a sequential basis, it was up a lot. So how -- what happened there? What went well? And how to think about it from here? And I had a follow-up.

    我想目前還沒有人問到造影劑診斷(pharm diagnostics)這塊。那表現非常強勁。Pete,請幫我們理解其中有多少是受益於去年同期因對比劑短缺所造成的比較基期(comps)。但即使我看這項業務的季對季表現,也大幅上升。所以——那裡發生了什麼?哪些做得很好?接下來該如何看待?我還有一個追問。

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • Yes, Larry, the real impact from a comp standpoint will be more in Q2. There really wasn't a negative effect last year. There was a little noise in it just relative to COVID coming out. But this is really about procedures growth and the need to do contrast-based imaging. If you think about particularly in CT in the vascular world, any type of intervention you're going to do intervascular, you're going to evaluate. You need to have a contrast agent, whether it'd be the brain throughout the body.

    是的,Larry。從比較基期的角度來看,真正的影響會更多出現在第二季。去年其實沒有明顯的負面影響;只是相對於 COVID 退潮有一些雜訊。但這主要是手術/處置量(procedures)成長,以及對比劑造影的需求所驅動。若你特別看 CT 在血管領域,任何你要做的血管內介入(intervascular intervention),你都需要先評估;你需要對比劑,不論是腦部或全身各部位。

  • And so it's showing that robustness there. We also have taken some, I would say, appropriate price increases to deal with escalating costs of things such as iodine. And so the combination in there is that procedures growth, which is driving our volume, but then also the pricing that we've taken place in PDx. And so we would expect that, that business is going to continue to put up strong numbers, both top and bottom the rest of the year.

    因此你看到那裡的韌性。我們也採取了一些我會說適當的漲價,以因應例如碘(iodine)等原物料成本上升。所以綜合來看,一方面是處置量成長帶動我們的出貨量,另一方面則是我們在 PDx 所實施的定價。基於此,我們預期該業務在今年剩餘時間,無論營收端或獲利端都將持續繳出強勁數字。

  • Helmut, would you add anything?

    Helmut,你要補充什麼嗎?

  • Helmut Zodl - CFO

    Helmut Zodl - CFO

  • Yes. Maybe I'll just add, because you may actually remember, Larry, in second quarter, where we had supply challenges in our factory in Shanghai. So there will be a higher growth in the second quarter. And then in the fourth quarter, we also had last year a small impact from inventory in the U.S. So there is also going to be higher growth during that quarter. So -- but overall, as Peter said, we're very happy, I think, with that business, I suppose the volume growth and also price is a strong contributor for the growth and margins, as you've seen, are quite strong and will continue to improve here.

    是的。我可能補充一下,因為你或許還記得,Larry,在第二季我們的上海工廠曾面臨供應挑戰。因此第二季的成長會更高。另外,去年第四季我們在美國的庫存也有一些小幅影響,所以那一季也會出現較高成長。不過整體而言,如 Peter 所說,我們對這項業務非常滿意;我想出貨量成長以及價格都是成長的重要貢獻者,而你也看到利潤率相當強勁,並且會在此持續改善。

  • Lawrence H. Biegelsen - Senior Medical Device Equity Research Analyst

    Lawrence H. Biegelsen - Senior Medical Device Equity Research Analyst

  • And Pete, obviously, we've seen immediate speculation on M&A involving GE Healthcare. And I know you won't comment on that specific asset. But can you comment on your thoughts on M&A in terms of deal size, areas of interest and financial criteria?

    Pete,顯然我們已經看到市場對涉及 GE Healthcare 的併購(M&A)出現即時的揣測。我知道你不會評論那個特定標的。但你能否談談你對 M&A 的看法,包括交易規模、感興趣的領域,以及財務標準?

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • Yes, Larry. Look, I mean we always are, as I've always mentioned, looking at M&A, I think it's a really important part of our DNA as a company, both to be really attentive to what's happening in our ecosystem and understanding where many of those deals will go. It's something that I started here, we do a weekly rhythm of looking at that whole atmosphere.

    是的,Larry。你看,我的意思是,我們一直都在——就像我一直提到的——關注 M&A。我認為這是我們公司 DNA 中非常重要的一部分:一方面要非常留意我們生態系中正在發生的事情,並理解許多交易可能會走向何處。這也是我到這裡後開始做的事情之一:我們每週都有固定節奏去檢視整個市場環境。

  • And if you think about IMACTIS and Caption are probably emblematic really what we look at. So again, to emphasize, with IMACTIS, it brought interventional biopsy capabilities into CT. We didn't have the best offering. This is going to give us a leadership offering to really fill out the capabilities to grow our business. I talked about capturing bringing artificial intelligence into point of care ultrasound to start, to make it more usable into populations of non-sonographers, which we think is a huge opportunity.

    如果你想想 IMACTIS 和 Caption,這兩個案例大概就很能代表我們在看什麼。再次強調,IMACTIS 為 CT 帶來介入式活檢能力;我們原本的產品供給並不是最強。這將讓我們擁有具領導地位的產品供給,真正補齊能力以擴大我們的業務。我也談到 Caption:先把人工智慧導入床邊超音波(point of care ultrasound),讓它對非超音波技師族群更容易使用,我們認為這是一個巨大的機會。

  • And so we look for technologies, both channel enablement as well as capabilities to enhance our overall strategy. And for the most part, they're typically tied into -- deep into our plans that we have already laid out. They help enhance, grow some of our businesses. And we have programs going on in all of our businesses, in Imaging, in Ultrasound, PCS as well as PDx. And I'd say one of the encouraging things are is there's a lot of interest out there, and we'll be disciplined in our approaches about how we look at them, but I think it's an important part of our growth strategy over the next 3 to 5 years.

    因此我們尋找的技術,包含通路賦能(channel enablement)以及強化能力,以提升我們的整體策略。大多數情況下,它們通常都與——與我們已經擬定的計畫深度連結;它們有助於強化並推動我們部分業務的成長。我們在所有業務中都有相關計畫,包括影像(Imaging)、超音波(Ultrasound)、PCS 以及 PDx。我想其中一個令人鼓舞的點是,市場上有很多機會與興趣;我們會以嚴謹自律的方式來評估,但我認為在未來 3 到 5 年,這將是我們成長策略中很重要的一部分。

  • Operator

    Operator

  • Our next question coming from the line of Veronika Dubajova with Citi.

    我們的下一個問題來自花旗(Citi)的 Veronika Dubajova。

  • Veronika Dubajova - Head of EMEA MedTech & Healthcare Services

    Veronika Dubajova - Head of EMEA MedTech & Healthcare Services

  • If I can just revert back to one of the themes that's come up and Pete, I just was hoping you could maybe talk a little bit in terms of the order dynamics that you're seeing, each of the 4 businesses are seeing the strongest order growth and maybe the type of products that you're seeing those most tractions for as you look at across that hospital CapEx landscape? Is it a premium? Is it low end? And kind of how you're thinking about that?

    如果我可以回到先前提到的一個主題,Pete,我希望你能談談你所看到的訂單動態:四個業務中各自看到最強的訂單成長的是哪些?以及在整體醫院資本支出(CapEx)環境下,你們看到最有牽引力的產品類型是什麼?是高階產品?還是入門低階?以及你們大致是如何思考這件事的?

  • And then maybe just to circle back to China and whether that stimulus program that you had talked about in prior quarters has now come to an end? And is that something that would have helped Q1? Or do you think it continues into Q2? And any comments you have on the competitive dynamics in China, in particular, in Imaging would be helpful as well.

    另外,也想再回到中國:你們在前幾季提到的那個刺激方案現在是否已經結束?那是否對第一季(Q1)有幫助?還是你認為會延續到第二季(Q2)?此外,也請就中國的競爭態勢發表一些看法,特別是在影像(Imaging)領域,會很有幫助。

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • Veronika, it was a little hard to hear, but I think the first question was around orders growth, different modalities, what's growing. And the second part was about China and some of the dynamics.

    Veronika,剛剛有點聽不清楚,但我想第一個問題是關於訂單成長、不同產品線/模態(modalities)哪些在成長;第二部分是關於中國以及一些相關動態。

  • Veronika Dubajova - Head of EMEA MedTech & Healthcare Services

    Veronika Dubajova - Head of EMEA MedTech & Healthcare Services

  • That's correct, yes.

    沒錯,是的。

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • Okay. So look, I think from an order standpoint and business growth, we're actually seeing nice growth and planning on it throughout the year. As you know, there are certain quarters in certain cyclical plays that, that promote others more or less. But I think from a standpoint of a lot of our bigger traditional diagnostic Imaging equipment, whether it would be MR, our molecular imaging portfolio between PET/CT, PET/MR, our new med cameras, we're seeing actually strong demand as well as CT and those tend to be the 3 big items.

    好的。首先,從訂單與業務成長的角度來看,我們其實看到不錯的成長,並且也規劃全年都會持續。如你所知,在某些具週期性的領域,不同季度會對某些品類有較多或較少的推動。但就我們許多較大型、傳統的診斷影像設備而言,不論是 MR、我們的分子影像產品組合(涵蓋 PET/CT、PET/MR)、我們新的核醫相機(med cameras),我們都看到強勁需求;同時 CT 也很強,而這些通常是三大重點項目。

  • I would say within our interventional world, particularly our surgery business with C-arms, with the growth of ambulatory surgical centers, those are strong growers.

    我會說在介入領域(interventional)方面,特別是我們的手術業務(surgery business)與 C-arm,隨著門診手術中心(ambulatory surgical centers)的成長,這些都是強勁的成長動能。

  • And then our Ultrasound business across the board has multiple opportunities. Our handheld business, in particular, women's health. And we would expect throughout the year, we had a strong cardiovascular quarter last quarter. We would expect that with the new launch of the Vivid product last year, the new Voluson product last year, all of those have 2 to 3 years until peak year sales that we'll continue to see that.

    接著,我們的超音波(Ultrasound)業務整體上有多項機會。我們的手持式(handheld)業務,特別是在女性健康方面。此外,我們預期全年會持續;上一季我們的心血管表現很強。我們也預期,隨著去年推出新的 Vivid 產品、去年推出新的 Voluson 產品,這些產品距離銷售達到峰值年(peak year sales)還有 2 到 3 年,我們會持續看到相關成長。

  • And I think you heard me mention around PCS, we actually, with fulfillment, we also have more sell and install opportunities as well. And I think the new monitoring platforms are going to drive growth and also the new anesthesia platform. So we see some pretty broad capabilities relative to our overall product. And then again, I'll just pull in PDx. But obviously, that's driven as a flow product tied to procedures. So we're seeing pretty broad strength across the board.

    另外,我想你也聽到我提到 PCS;我們在履約(fulfillment)的同時,也有更多銷售與安裝(sell and install)的機會。我認為新的監護平台(monitoring platforms)將帶動成長,新的麻醉平台(anesthesia platform)也是如此。因此,相對於我們整體產品組合,我們看到相當廣泛的能力。再者,我也把 PDx 納入考量;但很明顯,那是與手術量/處置量(procedures)連動的耗材型(flow)產品。所以我們看到整體各面向都相當強勁。

  • Helmut Zodl - CFO

    Helmut Zodl - CFO

  • And Veronika, I can cover the China question here. So we really saw strong growth in China was up double digit in the first quarter. And we expect that demand to continue. We see good momentum going to the second quarter. And really, I think China is really back, so the manufacturing sites are all operating, COVID, it has basically disappeared. So we're quite happy with the overall performance of our teams delivering for customers and patients.

    Veronika,我可以在這裡回答中國的問題。我們在中國第一季看到非常強勁的成長,達到雙位數成長。我們預期需求會持續,並看到進入第二季的良好動能。整體而言,我認為中國真的回來了:製造據點都在運作,COVID 基本上已經消失。因此,我們對團隊為客戶與病患交付成果的整體表現感到非常滿意。

  • And then the stimulus, the market will remain strong, whether there is a stimulus, and I belief still out there, and we feel quite optimistic about the rest of the year for our China market.

    至於刺激方案,不論是否有刺激,市場都會維持強勁;而我相信刺激仍然存在。我們對今年剩餘時間的中國市場相當樂觀。

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • Yes. And we've -- to your competitive question, I think dynamics, as we've been competing in China for many, many years, I don't think anything has fundamentally changed from that standpoint. We've really, as a multinational, led the pace of making sure that we have local content to be able to compete in tenders, making sure that we have local content to be able to have the cost positions to compete, and we believe we're in good shape to be able to do that. But as Helmut said, the bigger point here is after 2 years of COVID lockdowns, just like in the rest of the world, we would expect that there's some pent-up demand for procedures maybe latent disease, things of that nature that are going to drive the need for our products.

    是的。至於你問到的競爭問題,我認為我們在中國競爭多年,從這個角度看,競爭態勢並沒有根本性的改變。作為跨國公司,我們一直引領步伐,確保具備在地內容(local content)以便參與招標(tenders)競爭,也確保具備在地內容以取得具競爭力的成本結構(cost positions),我們相信我們在這方面狀況良好。但如 Helmut 所說,更重要的是:在經歷兩年的 COVID 封控之後,就像世界其他地方一樣,我們預期會有一些被壓抑的醫療需求(pent-up demand)與可能的潛在疾病(latent disease)等因素,將推動對我們產品的需求。

  • Operator

    Operator

  • And our next question coming from the line of Vijay Kumar with Evercore ISI.

    我們的下一個問題來自 Evercore ISI 的 Vijay Kumar。

  • Vijay Muniyappa Kumar - Senior MD and Head of Medical Supplies & Devices and Life Science Tools & Diagnostics Team

    Vijay Muniyappa Kumar - Senior MD and Head of Medical Supplies & Devices and Life Science Tools & Diagnostics Team

  • Congratulations on the Q1 print. Maybe my first one is here on the guidance here. Looks like Q1 off to a very strong start, perhaps coming in slightly above expectations, but the 5% to 7% was reiterated on the top line. Can you just talk about why the guidance perhaps the low end wasn't tweaked up? And clearly, that 12% in Q1, we've seen the backlog being worked through, component supplies getting better. How much of that back orders has been flushed out of the system? And how much is remaining? Perhaps some comment on how we should think about this guidance in back orders would be helpful.

    恭喜第一季(Q1)成績。我的第一個問題是關於指引(guidance)。看起來 Q1 開局非常強勁,可能略高於預期,但營收端仍重申 5% 到 7%。你能談談為什麼指引的低端沒有上調嗎?另外,Q1 的 12% 成長,我們看到積壓訂單(backlog)在消化、零組件供應改善。這些欠單(back orders)有多少已經從系統中清掉?還剩多少?也請談談我們應如何把指引與欠單的關係納入思考,會很有幫助。

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • Yes. Vijay, look, I think a good question. So first, it starts off, we're super happy and excited about our first quarter results. I think if -- how we expected it to play out, it really landed where we had hoped. And so that's a great result. I would say the big part here is what this does with a strong first quarter as it helps really derisk the back half of the year. We had quite a few questions talking about the ramp-up and how we thought about that profile. But that really helps derisk the backside of the year.

    是的,Vijay,這是個好問題。首先,我們對第一季的結果非常滿意也很興奮。就我們原先預期的走勢而言,實際落點確實符合我們的期待,所以這是很好的成果。我會說,強勁的第一季最重要的意義在於,它有助於降低下半年(back half of the year)的風險。我們之前收到不少關於爬坡(ramp-up)以及我們如何看待那個走勢的問題,但這確實有助於降低下半年的風險。

  • I think we're going to have better insights into kind of the macro discussions, where capital isn't items. As I've mentioned, we're cautiously optimistic right now. But with our first quarter as a stand-alone company, to get a few more months under our belt, and then we'll reevaluate it here as we finish second quarter and take a new look at how that is.

    我認為我們會對宏觀(macro)討論、以及資本項目(capital items)的情況有更好的洞察。如我提到的,我們目前是審慎樂觀(cautiously optimistic)。但作為一家獨立公司(stand-alone company)的第一季,我們希望再多累積幾個月的經驗,然後在第二季結束時重新評估,再重新檢視相關情況。

  • But at this point in time, again, we're cautiously optimistic that we're on track. And again, I think of it as, in many cases, kind of reducing that type of ramp that we already had within our initial plan.

    但就目前而言,我們仍審慎樂觀,認為我們在軌道上。再者,我把它視為在許多情況下,降低了我們原先初始計畫中已經納入的那種爬坡幅度。

  • Helmut Zodl - CFO

    Helmut Zodl - CFO

  • And Vijay, to your question around the backlog, obviously, delivering for patients and customers is really our top priority. So reducing the backlog is key. And in the quarter, we have an RPO of around $14.5 billion. It was very slightly up on a quarter-to-quarter basis. So despite the strong shipments and revenue delivery of 12%, the backlog actually was up sequentially.

    Vijay,關於你問到的積壓訂單(backlog),顯然為病患與客戶交付是我們的首要優先事項,因此降低積壓訂單是關鍵。本季我們的 RPO 約為 145 億美元,按季(quarter-to-quarter)僅小幅上升。因此,儘管出貨與營收交付強勁、達到 12%,積壓訂單仍呈現連續性上升(sequentially)。

  • And as I've commented before, we have on top of the RPO, we also have other backlog that is cancelable, where we have -- we see never really any major cancellations. So the total backlog is around $19 billion exiting the first quarter, which we are quite happy with, because this is going to take us well into '23. Some of these orders also go into '24. So we're quite happy where the backlog is at this stage.

    而且如我先前評論過的,除了 RPO 之外,我們還有其他可取消(cancelable)的積壓訂單;但我們幾乎沒有看到任何重大取消。因此,第一季結束時的總積壓訂單約為 190 億美元,我們對此相當滿意,因為這將支撐我們一路到 2023 年;其中部分訂單也會延伸到 2024 年。所以我們對目前的積壓訂單水位相當滿意。

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • Yes, at this point, I mean we're well positioned to obviously deliver upon our commitments. And again, if the year shapes up better, meaning that the macro environment improves and we get some better insights into how that plays out, particularly in markets like the United States, I think we're in very good shape to do better. But at this point in time, it's kind of prudent first quarter as a public company to kind of stay where we're at, and we're quite happy with the results.

    是的,就目前而言,我們的確處於有利位置,能夠交付我們的承諾。再者,如果今年的情勢更好——也就是宏觀環境改善,且我們對其發展有更清楚的洞察,特別是在美國等市場——我認為我們很有機會做得更好。但在此時點,作為一家上市公司(public company)的第一季,維持目前的指引是較為審慎的做法,而我們也對結果感到相當滿意。

  • Vijay Muniyappa Kumar - Senior MD and Head of Medical Supplies & Devices and Life Science Tools & Diagnostics Team

    Vijay Muniyappa Kumar - Senior MD and Head of Medical Supplies & Devices and Life Science Tools & Diagnostics Team

  • Absolutely. That makes sense. And then one follow-up on the margins here. Clearly, Q1 coming in, I thought Q1 margin performance was quite pleasing despite the spot buys. Can you comment on what the pricing versus inflation spot buy dynamics was in Q1? And when you think about that EPS guidance for the year, what has been assumed for FX for the year and the margin range of 50 to 100 basis points, perhaps should we be thinking about the higher end of the range?

    完全同意,這很合理。接著我有一個關於毛利率(margins)的追問。很明顯,Q1 的毛利率表現我覺得相當令人滿意,儘管有現貨採購(spot buys)。你能評論一下 Q1 的定價(pricing)相對於通膨、以及現貨採購動態的影響嗎?另外,談到全年 EPS 指引,全年假設的匯率(FX)是什麼?以及 50 到 100 個基點的毛利率區間(margin range),我們是否應該偏向區間的高端來思考?

  • Helmut Zodl - CFO

    Helmut Zodl - CFO

  • Yes, I can cover that your question here. So price and productivity was more than offsetting what we saw as inflation and our investment. So we were quite happy what we saw on price. Pete was commenting a little bit earlier, we typically see 2%, 3% in price, and we expect that it will lead to be delivered in 2023. So that was quite positive.

    是的,我可以在這裡回答你的問題。就價格與生產力而言,已經足以抵銷我們所看到的通膨以及我們的投資影響。因此,我們對價格表現相當滿意。Pete 先前也稍微提到,我們通常在價格上看到 2% 到 3% 的提升,我們預期這會在 2023 年落實交付。所以這是相當正面的。

  • In terms of currency, we saw a 4 percentage points impact on currency in the first quarter. For the full year, we're looking now at less than 1 percentage points of impact on currency to the top line. So it clearly has gotten slightly better. But as Peter said earlier, this is quite early in the year. This is our first quarter out here, and we're committed to the 50 basis points to 100 basis points of margin expansion for the full year.

    就匯率而言,我們在第一季看到匯率帶來 4 個百分點的影響。就全年來看,我們目前預估匯率對營收(top line)的影響將低於 1 個百分點。所以很明顯情況稍微好轉了。但如 Peter 先前所說,現在仍是年初,還很早。這是我們今年的第一季,我們仍致力於全年達成 50 到 100 個基點的利潤率擴張。

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • And I think, Vijay, we've talked about it and consistently is we expect our margin rate to be higher in the second half, given seasonality, but also productivity initiatives. And -- so we've got good progress on variable cost productivity, everything from logistics to other cost reductions. The thing we don't know is how that will play out with other cost of goods labor increases and items that are out there playing out. We think we've got very good plans to be able to deliver what we committed.

    而且我想,Vijay,我們一直都有談到並且一致的看法是:考量季節性以及生產力措施,我們預期下半年利潤率會更高。我們在變動成本生產力方面進展良好,從物流到其他成本降低皆是如此。我們不確定的是,這將如何與其他銷貨成本中的勞動力上升以及其他正在發生的項目相互作用。我們認為我們有非常好的計畫,能夠交付我們所承諾的成果。

  • If those were to improve, obviously, that would be a benefit that would come through in the P&L. But as Helmut said, it's still early in the year and we're on track to what we committed to.

    如果那些因素有所改善,顯然會成為損益表(P&L)上的一項利多。但如 Helmut 所說,現在仍是年初,我們正按計畫朝著我們所承諾的目標前進。

  • Operator

    Operator

  • And our last question coming from the line of Patrick Wood with Morgan Stanley.

    接下來我們的最後一個問題,來自摩根士丹利(Morgan Stanley)的 Patrick Wood。

  • Patrick Wood

    Patrick Wood

  • I've got 2 quick ones, which hopefully should be pretty easy. I guess the first is on counting. When you're thinking about that, the initial clinical data from some of your peers has been, I would argue, very strong versus base CT systems. So how do you view this technology? Do you view this as like marketing expansive and that you can get a good incremental price kicker on the back of these systems? Or do you view it as really a way to sort of increase barriers to entry and, I guess, consolidate share even more tightly amongst the top 2 providers relative to the broader pool? How are you thinking about that opportunity?

    我有兩個快速問題,希望都很容易。第一個是關於光子計數(photon counting)。當你們在思考這件事時,一些同業的初步臨床數據,我認為,相較於傳統 CT 系統非常強勁。你們如何看待這項技術?你們把它視為一種行銷上的擴張,並且可以在這些系統上取得不錯的增量價格溢價嗎?還是你們把它視為一種提高進入門檻的方法,並且相對於更廣泛的競爭者池,讓前兩大供應商能更緊密地鞏固市占?你們如何思考這個機會?

  • And are you thinking about it? Is this -- are we talking commercialization within a year or 2 years? Or is it a longer time frame on that for you?

    另外你們有在思考它嗎?我們談的是在 1 到 2 年內商業化嗎?還是你們的時間框架更長?

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • Yes. Look, good question. I would say the first answer is how we're thinking about is what it's going to do to help with diagnosis, patients and how it can change the game. I think we all think that photon counting has the potential to be a game changer. And the point being is it brings some of the capabilities of MR tissue characteristics and things of that nature that today, you don't get on a CT scanner. So I think at a high level, part of this is taking a look at and saying, the technology we're delivering on has the possibility to have many more, I'd say, energy separation levels, which actually can give you much more insights into what's actually happening at a molecular level, more so than the first-generation products, which are based on [CAD Tong] state for the most part. So that's part of it.

    是的。你問得很好。我想第一個回答是:我們思考的重點在於它將如何幫助診斷、幫助病患,以及它如何改變遊戲規則。我想我們都認為光子計數有潛力成為顛覆性技術(game changer)。重點在於,它把一些 MR 的能力(例如組織特性等)帶到 CT 上,而這些在今天的 CT 掃描儀上是做不到的。從高層次來看,其中一部分是檢視我們正在交付的技術,是否有可能提供更多的、我會說是能量分離層級,這實際上能讓你在分子層級上獲得更多洞見,甚至比第一代產品更多;第一代產品多半是基於 [CAD Tong] state。這是其中一部分。

  • I think, look, what we think is, over time, all scanners most likely will move to that direction. Is that 5 years, 10 years, I think that will be the adoption question. And a lot of that is about the cost curve. And our approach with deep silicone is based on the fact that we can actually ride a cost curve, we believe, more effectively than a rare element approach. And so that's how we think about that it will expand greatly.

    我想,我們的看法是,隨著時間推進,所有掃描儀很可能都會朝這個方向發展。至於是 5 年還是 10 年,我想那會是採用速度的問題,而其中很大一部分取決於成本曲線。我們以深矽(deep silicone)為基礎的方法,是基於我們相信相較於稀有元素(rare element)方案,我們能更有效地沿著成本曲線前進。因此我們認為它將會大幅擴展。

  • Obviously, as these products first come out over the next few years, they tend to be more elite, higher-priced products at select institutions, but we're thinking ahead about how we can bring this to more of the broader masses. So that's kind of it. We're very excited about it.

    顯然,這些產品在未來幾年剛推出時,往往會是更高端、價格更高的產品,先在特定機構導入;但我們也在提前思考,如何把它帶給更廣大的大眾市場。所以大致就是這樣。我們對此非常興奮。

  • I think it's a very interesting opportunity. If you think back to this whole point about characterization of diagnostics for drugs and things, photon counting will play a key role, we believe, in the future of that as well.

    我認為這是一個非常有趣的機會。如果你回頭想想我們提到的、關於藥物等的診斷特徵化(characterization)這整個方向,我們相信光子計數在其未來發展中也將扮演關鍵角色。

  • Patrick Wood

    Patrick Wood

  • And then time frame on commercialization, any indication of that for us?

    那商業化的時間表呢?對我們而言,有任何指引嗎?

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • Yes. We haven't communicated yet specifically what we're thinking about. We'll talk about that in upcoming meetings.

    是的。我們目前尚未對外具體溝通我們的想法。我們會在接下來的會議中談到。

  • Patrick Wood

    Patrick Wood

  • Sure. Totally understand. And then last one for me, I guess, more around the kind of Q1 and the recent trends you've seen. You've said earlier on the call, but any sense of how the demand is looking split by sort of new sockets versus replacement? Are you seeing a lot of new sockets come online? Or is it more of a replacement market in the current environment?

    好的,完全理解。那我最後一個問題,可能更聚焦在第一季以及你們近期看到的趨勢。你們先前在電話會議中提過,但能否談談需求在新裝機(new sockets)與汰換(replacement)之間的分布?你們是否看到很多新裝機上線?還是目前環境下更多是汰換市場?

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • Yes, it's a great question. And I would say it's a pretty good mix between the two. Certain geographies have different characteristics. As you could imagine, in an inland growing China market, it's heavy on new sockets. In Europe, believe it or not, we're trying to see a little bit more new than old because there's more outpatients opening up centers.

    是的,這是個很好的問題。我會說兩者的組合相當平均。不同地區有不同特性。你可以想像,在中國內陸成長型市場,新裝機占比很高。在歐洲,信不信由你,我們反而看到新裝機比舊機更多一些,因為有更多門診中心正在開設。

  • In the United States, it's probably a combination of 60-40 installed base or fleet renewals with new growth. And the new growth typically is tied to probably more of an outpatient imaging or tied to an ambulatory surgical center type environment.

    在美國,可能是 60/40 的組合:以既有裝機基礎或機隊更新(fleet renewals)為主,搭配新成長。而新成長通常與更多門診影像中心,或與門診手術中心(ambulatory surgical center)類型的環境相關。

  • Operator

    Operator

  • And that concludes the question-and-answer session. Speakers, please proceed with any closing remarks.

    問答環節到此結束。各位講者,請進行結語。

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • Thank you. So look, in closing, we're very pleased with the strong start to the year, and we see significant opportunities ahead of us as we continue to innovate and solve some of these big challenges that we've talked about that our customers face in delivering high-quality care in and outside the hospital in a very cost-effective way. And we look forward to keeping you updated on our progress. Thank you for joining our call today, and I'm sure we'll see many of you at some upcoming conferences. Thank you.

    謝謝。最後總結一下,我們對今年強勁的開局感到非常滿意;隨著我們持續創新,並解決我們所談到的、客戶在院內與院外以具成本效益的方式提供高品質照護所面臨的一些重大挑戰,我們也看到前方有顯著的機會。我們期待持續向各位更新我們的進展。感謝各位今天參與我們的電話會議,我相信我們會在接下來的一些會議上見到各位。謝謝。

  • Operator

    Operator

  • Ladies and gentlemen, this concludes today's conference. Thank you for participating. You may now disconnect.

    各位女士先生,今天的會議到此結束。感謝各位參與。您現在可以斷線。